THE METABOLISM OF URSODEOXYCHOLIC ACID IN MAN

本研究旨在探讨熊去氧胆酸在人体内的代谢规律。 患有胆结石的人类受试者接受熊去氧胆酸或 鹅去氧胆酸。具体地说，我们将进行临床试验，以 确定熊去氧胆酸是否是一种较好的溶石剂(胆结石 溶解)试剂优于鹅去氧胆酸，且副作用较少 在熊去氧胆酸治疗期间。其他参数将是 在本试验期间测量的数据包括：(A)池大小和日生产率： 同位素稀释技术(B)对肝微粒体HMG CoA还原酶的影响 和胆固醇7α-羟基酶活性(C)在细菌中的差异 鹅去氧胆酸7α和7β羟基的代谢 和熊去氧胆酸(D)对肠道胆固醇吸收的影响(E) 熊去氧胆酸的形成途径和组织部位。

This investigation aims to explore the metabolism of ursodeoxycholic acid in human subjects with gallstones treated either with ursodeoxycholic acid or chenodeoxycholic acid. Specifically, we will conduct a clinical trial to determine if ursodeoxycholic acid is a superior litholytic (gallstone dissolving) agent than chenodeoxycholic acid and if fewer side effects are noted during treatment with ursodeoxycholic acid. Other parameters that will be measured during this trial include (a) pool size and daily production rate by isotope dilution techniques (b) effect on hepatic microsomal HMG CoA reductase and cholesterol 7 alpha-hydroxylase activity (c) difference in the bacterial metabolism of the 7 alpha and 7 beta hydroxyl groups of chenodeoxycholic acid and ursodeoxycholic acid (d) effect on intestinal cholesterol absorption (e) pathway and tissue site of formation of ursodeoxycholic acid.